Hester Biosciences Ltd Consolidated Net Profit in Q1FY26 rise 131% to Rs. 17.30 crore

• The rise in net profit was driven by a turnaround in Hester Africa’s performance and improved cost control
• Revenue from operations for the Q1FY26 was reported at Rs.84.11 crore, rise of 2% Y-o-Y

Ahmedabad: 01 August 2025: Hester Biosciences Limited, one of India’s leading animal health company, manufacturing vaccines and health products has reported consolidated net profit of Rs. 17.30 crore for the Q1 FY25-26, rise of 131% as compared to the net profit of Rs. 7.49 crore reported in the first quarter of FY 2024-25. The rise in net profit was driven by a turnaround in Hester Africa’s performance and improved cost control. Revenue from operations of the company for the Q1FY26 was reported at Rs.84.11 crore, rise of 2% Y-o-Y as compared to the revenue from operations of Rs. 82.27 crore in the Q1FY25. Consolidated results include operations of subsidiaries from Nepal and Tanzania.

Gross margins remained stable due to an optimal product mix. The improvement in EBITDA and PAT margins reflects better absorption of fixed costs and cost optimisation measures across business functions.

Hester Africa delivered a net profit of Rs. 5.50 crore, marking a significant turnaround from a loss of Rs.  5.00 crore in Q1 FY25, on a topline of Rs.  17.23 crore, up from Rs.  2.80 crore in the corresponding period last year. This performance was supported by improved commercial execution and wider market penetration. With a stabilised manufacturing base in Tanzania and increased access to regional demand, Hester Africa is now well-positioned to scale its presence across the continent. The company is also expanding its footprint in high-priority markets to support future growth.

Hester Nepal contributed a net profit of INR 1.92 crore in Q1 FY26, compared to INR 2.73 crore in Q1 FY25, on a topline of INR 5.08 crore, versus INR 6.32 crore in the same period last year. The subsidiary continued to maintain a healthy presence in its market, executing key institutional orders and sustaining operational momentum. 

Animal Healthcare Division

In Q1 FY26, the division recorded a 33% decline in sales, primarily due to timing delays in key government Immunisation programmes for PPR and Lumpy Skin Disease, in which Hester’s PPR and Goat Pox vaccines respectively, are widely used, have got delayed. These programs, although delayed, are expected to roll out in the subsequent quarters.

Despite this temporary dip, the division maintained stable demand for the therapeutic products. Additionally, alternate products were introduced to mitigate earlier regulatory challenges and ensure product continuity in key markets.

Poultry Healthcare Division

The Poultry Healthcare Division recorded a 2% growth in Q1 FY26, led by robust demand for key vaccines, particularly for Newcastle Disease and Marek’s Disease.

New feed supplements and disinfectants launched last year are gaining acceptance, with anticipated stronger contribution in the upcoming quarters. The division also expanded its technical support initiatives and customer partnerships, reinforcing its position in a competitive market.

Way Forward

While the lower performance has been mainly due to external reasons which would get rectified in the coming quarters, internally, we have made structural changes in sales, marketing and in R&D divisions, the results of which would also be seen in the coming quarters.

Hester continues to strengthen its presence across key animal segments with a sharp focus on operational efficiency, new product development, and market expansion.

The company remains committed to:

1.     Launching its Avian Influenza vaccine and expanding the feed supplement and disinfectant portfolio.

2.     Accelerating product diversification in the Animal Healthcare division.

Leveraging its international infrastructure, particularly in Africa, to scale revenue and margins sustainably.

Disclaimer:
The information presented in this article is based on publicly available sources and company disclosures. It is intended solely for informational and educational purposes and should not be construed as investment, financial, or other professional advice. Smart Investment does not guarantee the accuracy, completeness, or timeliness of the information provided. Readers are strongly advised to conduct their own due diligence or consult with a qualified financial advisor before making any investment or business decisions. Smart Investment and its affiliates shall not be held liable for any losses or damages arising from the use of this content.